Nov 11 2011
Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN®.
Actavis has been manufacturing KADIAN® for 15 years and has in-depth expertise in the development and manufacturing of complex controlled-release pharmaceuticals.
KADIAN® US sales have grown 50% in the last 5 years to approximately $275 million for the 12 months ending September 30, 2011, according to IMS Health.
Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care